The proposed changes to Terminal Disclaimers aim to address high drug prices but lack statutory support and may face significant legal challenges.
The USPTO's change from 'obviousness-type double patenting' to 'nonstatutory double patenting' highlights a reliance on dubious policy arguments rather than solid legal foundations.
Collection
[
|
...
]